TY  - JOUR
T1  - Improved outcomes in heart failure treated with high-dose ace inhibitors and arbs: A population-based study
AU  - Egiziano G, Pilote L, Behlouli H, Daskalopoulou SS
Y1  - 2012/09/10
N1  - 10.1001/archinternmed.2012.2514
JO  - Archives of Internal Medicine
SP  - 1263
EP  - 1265
VL  - 172
IS  - 16
N2  - 
Elevated doses of angiotensin II–converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have similarly reduced morbidity and mortality in congestive heart failure (CHF) trials.1- 2 However, despite the recommendations of consensus CHF guidelines to achieve elevated target doses of ACE inhibitors or ARBs,3- 4 patients often receive doses that are lower than those used in large clinical trials, possibly owing to adverse effects.2,5- 6 We conducted a population-based retrospective cohort study to estimate the effect, in real-world clinical practice, of different doses of ACE inhibitors and ARBs on all-cause mortality and CHF readmission in patients with a first CHF admission.

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2012.2514
UR  - http://dx.doi.org/10.1001/archinternmed.2012.2514
ER  -